PDRN Skin Irritation Testing: Methods, Standards, and Regulatory Compliance

PDRN (polydeoxyribonucleotide) skin irritation testing is a critical safety evaluation required before PDRN-based skincare serums, injectables, and wound-care products can be released to market. Using validated protocols such as OECD TG 439, OECD TG 404, and ISO 10993-23, these tests confirm that PDRN formulations do not induce erythema, edema, or other adverse skin reactions. This guide explains the testing samples, evaluation items, methods, and regulatory applications involved in PDRN skin irritation assessment.

Technical Overview

PDRN (polydeoxyribonucleotide) is a linear polymer composed of deoxyribonucleotides, typically 50 to 2,000 base pairs in length, obtained through controlled fragmentation and purification of DNA derived most commonly from salmon milt. The compound is widely used in regenerative medicine and dermatology because it activates the adenosine A2A receptor, stimulating fibroblast proliferation, collagen synthesis, and angiogenesis, thereby accelerating tissue repair and improving skin barrier recovery.

Skin irritation testing for PDRN products is a core toxicological endpoint required before market release. Skin irritation is defined as the production of reversible inflammatory damage to the skin, manifested as erythema (redness) and edema (swelling), following contact with a test substance. The test confirms that PDRN-containing products, at their intended use concentration, do not provoke such reactions, thereby protecting consumers and satisfying the requirements of regulatory frameworks such as the OECD Testing Guidelines, the ISO 10993 series, and regional cosmetic and medical device regulations.

Because PDRN materials are applied both topically (serums, creams, masks) and parenterally (injectable regenerative solutions), the scope of irritation assessment spans in vitro reconstructed human epidermis models, in vivo rabbit studies, and human patch tests, with the method selected according to product type and destination market.

Testing Samples

Cosmetic and Skincare Products

• PDRN serums, ampoules, and essences at final formulation concentrations
• PDRN-containing creams, gels, and lotions
• Sheet masks and hydrogel patches infused with PDRN
• Post-procedure aftercare and skin barrier repair products

Medical and Aesthetic Products

• Injectable PDRN sodium solutions used in regenerative and mesotherapy treatments
• Combination products such as hyaluronic acid and PDRN dermal fillers
• PDRN wound dressings, films, and hydrogels
• Microneedle and transdermal delivery systems containing PDRN

Sample Preparation Requirements

Liquid samples are generally tested neat or diluted to the intended in-use concentration, with pH and osmolality documented because extreme values can confound results. Solid or polymeric medical device materials are prepared as extracts according to ISO 10993-12, using polar (e.g., saline) and non-polar (e.g., sesame oil) vehicles at standard extraction ratios such as 0.1 g/mL, 0.2 g/mL, or 6 cm²/mL. The testing laboratory also requires supporting documentation, including batch number, production date, composition, and intended use concentration.

Testing Items

The PDRN skin irritation test evaluates the following endpoints:

• Erythema and eschar formation, scored on the Draize 0 to 4 scale
• Edema formation, scored on the Draize 0 to 4 scale
• Primary Irritation Index (PII) calculated from graded responses
• Tissue viability percentage measured by MTT reduction in in vitro RhE models
• Optional mechanistic markers such as IL-1α, IL-6, and IL-8 release for research-grade characterization

Classification outcomes follow UN GHS categories: samples that reduce mean tissue viability to 50% or below, or that produce irritant scores in vivo, are classified as Category 2 skin irritants, while products exceeding these thresholds are considered non-irritant (No Category). For cosmetic claims, stricter internal acceptance criteria, often requiring relative viability of 80% to 90% or higher versus the negative control, are typically applied to ensure a clear margin of safety.

Testing Methods

In Vitro Reconstructed Human Epidermis (RhE) Test: OECD TG 439

Validated three-dimensional skin models such as EpiDerm (EPI-200), EpiSkin, and SkinEthic RHE are used. A defined dose of the PDRN test sample, typically 30 μL for liquids or 25 mg for solids applied with wetting, is dosed topically onto the tissue surface, followed by an exposure period of approximately 15 to 60 minutes depending on the model and a post-treatment incubation of about 42 hours. Cell viability is then quantified by MTT conversion. A mean tissue viability above 50% relative to the negative control indicates that the sample is not classified as a skin irritant. This method is accepted for GHS classification of chemicals and is the primary animal-free approach used in the cosmetics sector.

In Vivo Acute Dermal Irritation: OECD TG 404 / ISO 10993-23

Where animal testing is permitted or required, a single 4-hour semi-occlusive application of the test substance is made to the clipped dorsal skin of usually three healthy rabbits. Test sites are examined and scored for erythema and edema at 1, 24, 48, and 72 hours after patch removal using the Draize grading scale. The Primary Irritation Index is derived by dividing the sum of all scores by the total number of readings, and results are interpreted as non-irritant (PII of 0), mildly irritating (PII below 2), moderately irritating (PII of 2 to 5), or severely irritating (PII above 5). For medical devices, ISO 10993-23 governs the procedure, including intracutaneous reactivity testing with polar and non-polar extracts, which is particularly relevant for injectable PDRN products that bypass the intact skin barrier.

Human Skin Patch Testing

Finished cosmetic products intended for skin contact are commonly verified through controlled human patch tests conducted under dermatological supervision. Options include a single 4-hour occlusive patch on the upper back or forearm, 48-hour semi-occlusive patches, and cumulative protocols such as the repeated-insult or 21-day cumulative patch test for stronger claim support. Panels typically comprise 25 to 35 healthy volunteers of diverse phototypes, with reactions graded at patch removal and at 24, 48, and 72 hours afterward. A well-conducted study provides direct evidence for marketing claims such as "dermatologically tested" or "non-irritating."

Test Selection Strategy

An integrated strategy is recommended in practice: in vitro RhE screening during formulation development, regulatory in vitro or in vivo studies according to destination-market rules, and human patch testing for final claim substantiation. Injectable products additionally require intracutaneous reactivity data because they are administered beneath the skin surface and therefore fall under medical device biocompatibility requirements.

Applications

PDRN skin irritation test results serve multiple purposes across the product lifecycle:

• Regulatory submissions for cosmetic registration and notification with authorities such as NMPA, MFDS, and EU CPNP responsible persons
• Biological evaluation of PDRN medical devices under ISO 10993-1 and ISO 10993-23
• Substantiation of safety claims including "non-irritating," "sensitive skin compatible," and "dermatologist tested"
• Formulation optimization, including comparison of PDRN concentration levels and excipient interactions
• Quality control and batch release support for manufacturers of PDRN raw materials and finished goods
• Dossier support for contract manufacturers and brand owners entering multiple international markets

FAQ

Why does PDRN require skin irritation testing if it is biologically derived?

Although PDRN originates from salmon DNA and is generally well tolerated, biological origin does not guarantee safety. Residual impurities, extraction solvents, formulation excipients, pH, and osmolality can all influence local tolerance. Independent irritation testing verifies the safety of the finished product as it is actually used.

Which method should be chosen for a PDRN cosmetic serum?

An in vitro RhE test (OECD TG 439) is the standard screening tool and satisfies animal-testing bans in regions such as the EU. Human patch testing is then used to support final marketing claims. In vivo rabbit testing is generally unnecessary for cosmetics and is restricted in many jurisdictions.

How long does the test take?

In vitro RhE studies are typically completed within one to two weeks of sample receipt. In vivo rabbit studies require approximately two to four weeks including acclimatization and observation. Human patch tests, depending on protocol, generally run three to six weeks from panel recruitment to final report.

How much sample is required?

For in vitro testing, approximately 20 to 50 mL or grams of the finished product is usually sufficient. In vivo intracutaneous studies may require more material depending on extraction ratios and the number of test and control sites. Human patch testing typically needs 30 to 100 mL. Exact requirements should be confirmed with the testing laboratory before submission.

What constitutes a passing result?

In the in vitro RhE test, mean tissue viability above 50% of the negative control indicates no classification as a skin irritant. In vivo, a Primary Irritation Index of essentially zero across all animals and time points supports a non-irritant designation. For consumer-facing claims, brands commonly apply stricter internal thresholds to ensure a clear safety margin.